Literature DB >> 810573

Scopolamine effects on visual discrimination: modifications related to stimulus control.

H L Evans.   

Abstract

Stumptail monkeys (Macaca arctoides) performed a discrete trial, three-choice visual discrimination. The discrimination behavior was controlled by the shape of the visual stimuli. Strength of the stimuli in controlling behavior was systematically related to a physical property of the stimuli, luminance. Low luminance provided weak control, resulting in a low accuracy of discrimination, a low response probability and maximal sensitivity to scopolamine (7.5--60 mug/kg). In contrast, high luminance provided strong control of behavior and attenuated the effects of scopolamine. Methylscopolamine had no effect in doses of 30 to 90 mug/kg. Scopolamine effects resembled the effects of reducing stimulus control in undrugged monkeys. Since behavior under weak control seems to be especially sensitive to drugs, manipulations of stimulus control may be particularly useful whenever determination of the minimally-effective dose is important, as in behavioral toxicology. Present results are interpreted as specific visual effects of the drug, since nonsensory factors such as base-line response rate, reinforcement schedule, training history, motor performance and motivation were controlled. Implications for state-dependent effects of drugs are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 810573

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Effects of cholinergic and non-cholinergic drugs on visual discrimination and delayed visual discrimination performance in rats.

Authors:  J S Andrews; M Grützner; D N Stephens
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Effects of scopolamine on learning and memory in monkeys.

Authors:  U C Savage; W B Faust; P Lambert; J M Moerschbaecher
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

3.  Pharmacological evidence is consistent with a prominent role of spatial memory in complex navigation.

Authors:  Timothy C Roth; Aaron R Krochmal
Journal:  Proc Biol Sci       Date:  2016-02-10       Impact factor: 5.349

4.  Using Pharmacological Manipulation and High-precision Radio Telemetry to Study the Spatial Cognition in Free-ranging Animals.

Authors:  Timothy C Roth; Aaron R Krochmal; William B Gerwig; Sage Rush; Nathaniel T Simmons; Jeffery D Sullivan; Katrina Wachter
Journal:  J Vis Exp       Date:  2016-11-06       Impact factor: 1.355

5.  Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects.

Authors:  N M Rupniak; M J Steventon; M J Field; C A Jennings; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  A comparison of scopolamine and biperiden as a rodent model for cholinergic cognitive impairment.

Authors:  Inge Klinkenberg; Arjan Blokland
Journal:  Psychopharmacology (Berl)       Date:  2011-02-19       Impact factor: 4.530

7.  Cholinergic learning deficits in the marmoset produced by scopolamine and ICV hemicholinium.

Authors:  R M Ridley; N G Barratt; H F Baker
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Effects of physostigmine and scopolamine on rats' performances in object-recognition and radial-maze tests.

Authors:  A Ennaceur; K Meliani
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Dynamic causal modelling of precision and synaptic gain in visual perception - an EEG study.

Authors:  Harriet R Brown; Karl J Friston
Journal:  Neuroimage       Date:  2012-06-29       Impact factor: 6.556

10.  Muscarinic Attenuation of Mnemonic Rule Representation in Macaque Dorsolateral Prefrontal Cortex during a Pro- and Anti-Saccade Task.

Authors:  Alex J Major; Susheel Vijayraghavan; Stefan Everling
Journal:  J Neurosci       Date:  2015-12-09       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.